Kellanova (K) concluded trading on Thursday at a closing price of $82.21, with 4.12 million shares of worth about $338.97 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 10.35% during that period and on February 13, 2025 the price saw a gain of about 0.04%. Currently the company’s common shares owned by public are about 345.00M shares, out of which, 293.55M shares are available for trading.
Stock saw a price change of 0.10% in past 5 days and over the past one month there was a price change of 0.96%. Year-to-date (YTD), K shares are showing a performance of 1.53% which increased to 50.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $52.46 but also hit the highest price of $82.34 during that period. The average intraday trading volume for Kellanova shares is 2.09 million. The stock is currently trading 0.37% above its 20-day simple moving average (SMA20), while that difference is up 1.13% for SMA50 and it goes to 12.07% higher than SMA200.
Kellanova (NYSE: K) currently have 345.00M outstanding shares and institutions hold larger chunk of about 66.35% of that.
The stock has a current market capitalization of $28.34B and its 3Y-monthly beta is at 0.32. PE ratio of stock for trailing 12 months is 21.24, while it has posted earnings per share of $3.87 in the same period. Its PEG reads 5.74 and has Quick Ratio of 0.56 while making debt-to-equity ratio of 1.68. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for K, volatility over the week remained 0.22% while standing at 0.32% over the month.
Stock’s fiscal year EPS is expected to drop by -0.44% while it is estimated to increase by 5.64% in next year. EPS is likely to shrink at an annualized rate of 3.70% for next 5-years, compared to annual growth of 6.75% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Exane BNP Paribas on November 01, 2024 offering a Neutral rating for the stock and assigned a target price of $83 to it. Stock get a Neutral rating from Goldman on August 12, 2024.
